DYSIS Medical Appoints New CEO and Chief Commercial Officer

DYSIS Medical Ltd., developer of the DYSIS Ultra Colposcope used in cervical cancer screening, has appointed Darin Hammers as CEO and a member of the board of directors. In addition, Michael Gioffredi was appointed as chief commercial officer (CCO). Former CEO Alastair Atkinson will remain with the company and assume the role of chief operating officer.
 
Prior to joining DYSIS, Hammers was president and CEO of Cogentix Medical, which was acquired by Laborie in April 2018. Hammers’ experience includes over 25 years of leadership roles in urology and gynecology organizations. Prior to joining Cogentix, Hammers was vice president of Sales for the Bard Medical Division of C.R. Bard and prior to that, spent over 12 years with Boston Scientific Corp. in various leadership positions focused on urology and gynecology products.

Hammers earned an MBA from Emory University’s Goizueta School of Business and a bachelor of science degree in marketing from the University of Southern Indiana.
 
Gioffredi joins DYSIS with over 35 years of medical device experience in sales and marketing leadership positions. Gioffredi was previously president of North America for Lombard Medical Technologies, which was acquired by MicroPort Medical. Prior to Lombard, he was CCO for Vessix Vascular, a venture capital-backed medical device company that was acquired by Boston Scientific Corp. in late 2012. Gioffredi also served as senior vice president of Sales and Marketing for Angioscore Inc., a venture capital funded company that was acquired by Spectranetics Corporation.

Gioffredi earned a bachelor of arts in business administration and marketing from California State University in Fullerton.
 
“We believe that Mr. Hammers and Mr. Gioffredi have the right leadership experience and knowledge of the U.S. medical device market to establish DYSIS as the leader in colposcopy. On behalf of all stakeholders, we welcome them to DYSIS,” said Casper Breum, senior partner of Lundbeckfonden Ventures. Lundbeckfonden Ventures, based in Copenhagen, Denmark, committed $25 million to DYSIS in mid 2018 as part of a plan to grow the business by accelerating U.S. commercial operations.
 
The DYSIS Colposcope employs patented optical imaging and software technology to scan a patient’s cervix, quantify the results and present them to a clinician in the form of an intuitive color-coded map (DYSISmap). Patients appreciate the ability to view their own DYSISmap during the examination, improving understanding and reducing anxiety.
 
DYSIS Medical Ltd. is based in Edinburgh, United Kingdom, and Atlanta, Ga.. The company is committed to early detection and diagnosis of cervical disease using biophotonic innovations. DYSIS is committed to becoming the global leader in automated optical molecular imaging technologies for medical diagnostic and screening applications.